Amarin (AMRN) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Amarin (AMRN) over the past year, gaining 52.4% versus a loss of 35.5%. Over five years, AMRN leads with a -85.5% price change compared with -98.3% for INDP. Amarin is the larger company by market cap ($444.4 million vs $433.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | INDP |
|---|---|---|
| Share price | $10.57 | $2.82 |
| Market cap | $444.39M | $433.16M |
| 1-day change | -6.13% | -9.90% |
| YTD return | -24.28% | -3.09% |
| 1-year return | -35.47% | +52.43% |
| 5-year return | -85.48% | -98.26% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | — |
| Revenue growth (YoY) | -6.55% | — |
| Net income (latest FY) | $-38.80M | $-20.85M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | — |
| Net margin | -18.16% | — |
| 52-week high | $17.31 | $5.96 |
| 52-week low | $10.56 | $0.92 |
| Distance from 52-week high | -38.94% | -52.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +22.99% | — |
| Average volume | 79.50K | 712.87K |
| Shares outstanding | 42.04M | 153.60M |
| Employees | 80 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed AMRN by 87.9 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
AMRN vs INDP FAQ
Which is bigger, Amarin or Indaptus Therapeutics?
Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $433.16M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, AMRN or INDP?
INDP returned +52.43% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.